American Society of Nuclear Cardiology (ASNC) President Rob Beanlands, M.D., shares a couple trends he sees in cardiac nuclear imaging.
Molecular Imaging
Molecular imaging is a diagnostic imaging procedure that provides detailed images of how the body is funtioning at the molecular and cellular level. It also includes nuclear imaging.
-
-
Piotr Slomka explains how his team at Cedars-Sinai is working on intelligent patient risk prediction algorithms...
-
Doctor Robert Hendel explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at the American Society of Nuclear Cardiology (ASNC) 2019 meeting...
-
November 5, 2019 — Philips Medical System is recalling the Forte Gamma Camera System due to the potential for the 660-pound detector to detach from the device without warning.
This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topic at the conference.
Feature | Nuclear Imaging | November 22, 2019 | Dave Fornell, Editor
There were a few key takeaways from the American Society of Nuclear...
Rupa Sanghani, M.D., FASNC, associate professor, Rush Medical College, director of nuclear cardiology and stress laboratory, Rush University Medical Center, and associate director, Rush Heart Center for Women, explains how to create a high-volume cardiac positron emission tomography (PET) imaging program. She spoke on this topic at the 2019 meeting of the American Society Nuclear Cardiology (ASNC) and led a tour with attendees of the PET-CT system at Rush, which was located close to the conference. #ASNC
Gallery | ASNC | November 11, 2019
This is a photo essay of new technologies and activities at the ...
Videos | Nuclear Imaging | November 07, 2019
Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can bee seen in this photo on either side of the patient bed. These can be rotated above the patient.
Feature | Molecular Imaging | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — Philips Medical System is recalling the Forte Gamma Camera System due to the potential for the...
News | Radiopharmaceuticals and Tracers | August 02, 2019
August 2, 2019 — The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution...
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.
Feature | Nuclear Imaging | July 22, 2019 | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS
Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the...
News | Radiopharmaceuticals and Tracers | July 16, 2019
July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot...
Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.
News | Cardiac Imaging | June 07, 2019
June 7, 2019 — The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the...
News | Radiopharmaceuticals and Tracers | June 05, 2019
June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel...
News | Radiopharmaceuticals and Tracers | May 17, 2019
May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b...
